Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin‐1

[1]  A. Protter,et al.  Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide. , 1998, The Journal of pharmacology and experimental therapeutics.

[2]  Omapatrilat, a novel cardiovascular agent, improves hemodynamics in patients with heart failure , 1998 .

[3]  J. Cleland,et al.  Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure , 1998, The Lancet.

[4]  K. Swedberg,et al.  Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure , 1998, The Lancet.

[5]  D. Webb,et al.  Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade Mediated Vasodilatation Is Attenuated by Inhibition of − Endothelin-A Receptor Antagonist , 1998 .

[6]  W. Abraham,et al.  Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.

[7]  M. Packer,et al.  MULTICENTER, DOUBLEBLIND PLACEBO CONTROLLED STUDY OF LONG TERMENDOTHELIN BLOCKADE WITH BOSENTAN IN CHRONIC HEART FAILURE RESULTS OF THE REACH-1 TRIAL. ABSTRACT , 1998 .

[8]  A. Richards,et al.  Infusion or co-infusion of brain natriuretic peptide and/or adrenomedullin in human heart failure , 1998 .

[9]  G. Cooper,et al.  Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. , 1997, Circulation.

[10]  S. Barker,et al.  Adrenomedullin acts as a local mediator of vascular homeostasis through interactions which lead to reduced endothelin-1 synthesis and secretion , 1997, Journal of Human Hypertension.

[11]  L. Malendowicz,et al.  Effects of adrenomedullin on the human adrenal glands: an in vitro study. , 1997, The Journal of clinical endocrinology and metabolism.

[12]  N. Arakawa,et al.  Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. , 1997, Circulation.

[13]  B. Cheung,et al.  Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders. , 1997, Clinical science.

[14]  D. Heitjan,et al.  Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. , 1996, Circulation.

[15]  K. Buchanan,et al.  Adrenomedullin: a novel cardiovascular regulatory peptide. , 1996, QJM : monthly journal of the Association of Physicians.

[16]  D. Webb,et al.  Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. , 1996, Circulation.

[17]  L. Miller,et al.  Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1996, The American journal of cardiology.

[18]  K. Kitamura,et al.  Inhibition of aldosterone production by adrenomedullin, a hypotensive peptide, in the rat. , 1996, Hypertension.

[19]  R. Rodeheffer,et al.  Cardiac secretion of adrenomedullin in human heart failure. , 1996, The Journal of clinical investigation.

[20]  D. Webb,et al.  Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. , 1996, Circulation.

[21]  Y. Koiwaya,et al.  Increased plasma adrenomedullin levels in chronic congestive heart failure. , 1996, American heart journal.

[22]  A. Lerman,et al.  Enhanced Coronary Vasoconstriction to Endothelin-BReceptor Activation in Experimental Congestive Heart Failure , 1996 .

[23]  A. Lerman,et al.  Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. , 1996, Circulation.

[24]  T. Ishimitsu,et al.  Increased plasma levels of adrenomedullin in patients with heart failure. , 1995, Journal of the American College of Cardiology.

[25]  M. Fujishima,et al.  Cardiovascular and neurohormonal effects of intravenous adrenomedullin in conscious rabbits. , 1995, The American journal of physiology.

[26]  P. Hunziker,et al.  Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.

[27]  O. Kida,et al.  HAEMODYNAMIC RESPONSES TO RAT ADRENOMEDULLIN IN ANAESTHETIZED SPONTANEOUSLY HYPERTENSIVE RATS , 1995, Clinical and experimental pharmacology & physiology.

[28]  J. Burnett,et al.  Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. , 1995, Circulation.

[29]  T. Horio,et al.  Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. , 1995, Hypertension.

[30]  J. Cleland,et al.  Renal response to candoxatrilat in patients with heart failure. , 1995, Journal of the American College of Cardiology.

[31]  S. Gardiner,et al.  Regional haemodynamic effects of human and rat adrenomedullin in conscious rats , 1995, British journal of pharmacology.

[32]  T. Yamaguchi,et al.  Effect of adrenomedullin on aldosterone secretion by dispersed rat adrenal zona glomerulosa cells. , 1994, Life sciences.

[33]  P. Nihoyannopoulos,et al.  Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? , 1994, European heart journal.

[34]  D. Webb,et al.  Contribution of endogenous generation of endothelin-1 to basal vascular tone , 1994, The Lancet.

[35]  N. Minamino,et al.  Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. , 1994, Biochemical and biophysical research communications.

[36]  K. Miyamoto,et al.  Endothelial cells actively synthesize and secrete adrenomedullin. , 1994, Biochemical and biophysical research communications.

[37]  W. Summer,et al.  Adrenomedullin dilates the pulmonary vascular bed in vivo. , 1994, Journal of applied physiology.

[38]  W. Edwards,et al.  Endothelin in human congestive heart failure. , 1994, Circulation.

[39]  K. Kangawa,et al.  Immunoreactive adrenomedullin in human plasma , 1994, FEBS letters.

[40]  D. Kohan.  Endothelins in the kidney: physiology and pathophysiology. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  K. Miyatake,et al.  Rapid increase in plasma endothelin concentrations during percutaneous balloon dilatation of the mitral valve in patients with mitral stenosis. , 1993, British heart journal.

[42]  G. Riegger,et al.  Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. , 1992, The American journal of cardiology.

[43]  P. Binkley,et al.  Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[44]  F. Marumo,et al.  Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. , 1991, The American journal of cardiology.

[45]  H. Imura,et al.  Hemodynamic, Renal, and Hormonal Responses to Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure , 1991, Circulation.

[46]  M. Shichiri,et al.  Cellular Mechanism of Endothelin‐1 Release by Angiotensin and Vasopressin , 1991, Hypertension.

[47]  A. Jardine,et al.  Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. , 1990, American journal of hypertension.

[48]  L. V. von Segesser,et al.  Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? , 1990, Circulation.

[49]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[50]  J. Cohn,et al.  The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.

[51]  P. Harris.  Evolution and the cardiac patient. , 1983, Cardiovascular research.